FDA panel backs Amgen's cholesterol drug for high-risk patients

June 10, 2015 8:37 PM

29 0

WASHINGTON, June 10 An advisory panel to the U.S. Food and Drug Administration recommended approval of Amgen Inc's cholesterol-lowering drug Repatha but said it should be only used in patients at high risk of cardiovascular disease.

The panel voted unanimously to approve the drug, known also as evolocumab, for patients with homozygous familial hypercholesterolemia (HoFH), a hereditary disorder that causes high LDL and can cause heart attacks in very young people, including children.

Also read: FDA approves BioMarin rare metabolic disorder drug, shares rise

Read more

To category page